Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

CONCLUSIONS: Among patients with resected ALK-positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann-La Roche; ALINA ClinicalTrials.gov number, NCT03456076.).PMID:38598794 | DOI:10.1056/NEJMoa2310532

Source: Cancer Control - April 10, 2024 Category: Cancer & Oncology Authors: Yi-Long Wu Rafal Dziadziuszko Jin Seok Ahn Fabrice Barlesi Makoto Nishio Dae Ho Lee Jong-Seok Lee Wenzhao Zhong Hidehito Horinouchi Weimin Mao Maximilian Hochmair Filippo de Marinis M Rita Migliorino Igor Bondarenko Shun Lu Qun Wang Tania Ochi Lohmann Tin Source Type: research